168 related articles for article (PubMed ID: 14988091)
1. Imatinib attenuates diabetes-associated atherosclerosis.
Lassila M; Allen TJ; Cao Z; Thallas V; Jandeleit-Dahm KA; Candido R; Cooper ME
Arterioscler Thromb Vasc Biol; 2004 May; 24(5):935-42. PubMed ID: 14988091
[TBL] [Abstract][Full Text] [Related]
2. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice.
Lewis P; Stefanovic N; Pete J; Calkin AC; Giunti S; Thallas-Bonke V; Jandeleit-Dahm KA; Allen TJ; Kola I; Cooper ME; de Haan JB
Circulation; 2007 Apr; 115(16):2178-87. PubMed ID: 17420349
[TBL] [Abstract][Full Text] [Related]
3. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
Candido R; Allen TJ; Lassila M; Cao Z; Thallas V; Cooper ME; Jandeleit-Dahm KA
Circulation; 2004 Mar; 109(12):1536-42. PubMed ID: 15023892
[TBL] [Abstract][Full Text] [Related]
4. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice.
Candido R; Jandeleit-Dahm KA; Cao Z; Nesteroff SP; Burns WC; Twigg SM; Dilley RJ; Cooper ME; Allen TJ
Circulation; 2002 Jul; 106(2):246-53. PubMed ID: 12105166
[TBL] [Abstract][Full Text] [Related]
5. Protective role of imatinib in atherosclerosis.
Kadowaki T; Kubota N
Arterioscler Thromb Vasc Biol; 2004 May; 24(5):801-3. PubMed ID: 15132971
[No Abstract] [Full Text] [Related]
6. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.
Lassila M; Jandeleit-Dahm K; Seah KK; Smith CM; Calkin AC; Allen TJ; Cooper ME
J Am Soc Nephrol; 2005 Feb; 16(2):363-73. PubMed ID: 15625075
[TBL] [Abstract][Full Text] [Related]
7. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
8. Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice.
Bu DX; Rai V; Shen X; Rosario R; Lu Y; D'Agati V; Yan SF; Friedman RA; Nuglozeh E; Schmidt AM
Circ Res; 2010 Apr; 106(6):1040-51. PubMed ID: 20133903
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
10. Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors.
Chu S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2008 Jan; 108(1):182-90. PubMed ID: 18028988
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension.
Jang SW; Ihm SH; Choo EH; Kim OR; Chang K; Park CS; Kim HY; Seung KB
Hypertension; 2014 Jun; 63(6):1228-34. PubMed ID: 24591339
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.
Aoki M; Nabeshima K; Koga K; Hamasaki M; Suzumiya J; Tamura K; Iwasaki H
Lab Invest; 2007 Aug; 87(8):767-79. PubMed ID: 17558420
[TBL] [Abstract][Full Text] [Related]
13. LRP: role in vascular wall integrity and protection from atherosclerosis.
Boucher P; Gotthardt M; Li WP; Anderson RG; Herz J
Science; 2003 Apr; 300(5617):329-32. PubMed ID: 12690199
[TBL] [Abstract][Full Text] [Related]
14. Oral flavonoid supplementation attenuates atherosclerosis development in apolipoprotein E-deficient mice.
Hishikawa K; Nakaki T; Fujita T
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):442-6. PubMed ID: 15499038
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.
van Steensel L; Paridaens D; Schrijver B; Dingjan GM; van Daele PL; van Hagen PM; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3091-8. PubMed ID: 19234339
[TBL] [Abstract][Full Text] [Related]
16. Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma.
Kodama M; Kitadai Y; Sumida T; Ohnishi M; Ohara E; Tanaka M; Shinagawa K; Tanaka S; Yasui W; Chayama K
Cancer Sci; 2010 Sep; 101(9):1984-9. PubMed ID: 20624165
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
18. Role of Src tyrosine kinases in experimental pulmonary hypertension.
Pullamsetti SS; Berghausen EM; Dabral S; Tretyn A; Butrous E; Savai R; Butrous G; Dahal BK; Brandes RP; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Rosenkranz S; Schermuly RT
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1354-65. PubMed ID: 22516066
[TBL] [Abstract][Full Text] [Related]
19. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells.
Malavaki CJ; Roussidis AE; Gialeli C; Kletsas D; Tsegenidis T; Theocharis AD; Tzanakakis GN; Karamanos NK
FEBS J; 2013 May; 280(10):2477-89. PubMed ID: 23374223
[TBL] [Abstract][Full Text] [Related]
20. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Abrams TJ; Lee LB; Murray LJ; Pryer NK; Cherrington JM
Mol Cancer Ther; 2003 May; 2(5):471-8. PubMed ID: 12748309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
